---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-25-034733"
form_type: "8-K"
ticker: "OVID"
cik: "0001636651"
company_name: "Ovid Therapeutics Inc."
filed_at: "2025-07-10T23:59:59+00:00"
generated_at: "2026-05-18T08:46:15.314678+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Ovid Therapeutics shareholders approve reverse stock split authorization at annual meeting

## Summary
- Elected directors Kevin Fitzgerald and Bart Friedman to three-year terms with >35M votes for each.
- Advisory say-on-pay approved, 35.4M for vs 0.9M against (95% of votes cast).
- Ratified KPMG as independent auditor for FY2025, 50.8M for vs 0.2M against.
- Authorized board to implement reverse stock split at ratio 1:10 to 1:40, at board's discretion (44.2M for).

## SEC filing metadata
- accession: 0001628280-25-034733
- form_type: 8-K
- ticker: OVID
- cik: 0001636651
- company_name: Ovid Therapeutics Inc.
- filed_at: 2025-07-10T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1636651/000162828025034733/0001628280-25-034733-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1636651/000162828025034733/ovid-20250710.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-25-034733
- JSON: https://secwatch.observer/filing/0001628280-25-034733.json
- Plain text: https://secwatch.observer/filing/0001628280-25-034733.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.